In this study we assessed the relative abundance levels of PGHS-1 and PGHS-2 mRNA in human fetal lung, kidney, and small intestine during each trimester and in the first 9 days of life in babies born at term. We observed a decrease or no change in mRNA levels for PGHS-1 from the first trimester to the third trimester, whereas PGHS-2 mRNA levels were low in the first trimester, increased significantly in the second and third trimesters, and in the case of lung and kidney increased further in the newborn infant.
Material and methods
Ethical approval for the study was obtained, and appropriate collection procedures were followed at each institution. Human embryonic and fetal tissues were obtained at elective abortion by the Central Laboratory for Human Embryology, University of Washington, Seattle. This laboratory supplied tissues from normal fetuses from 54 days to 20 weeks of gestation. Specimens were obtained within minutes of passage (by vacuum aspiration), and tissues were aseptically identified and immediately snap frozen in liquid nitrogen. Preparation time for the tissue was always <20 minutes. Samples were shipped on dry ice and stored at -80°C until assayed.
Tissues from third-trimester and term fetuses that died in utero were obtained from patients by cesarean delivery in the absence of labor (defined as ≤1 uterine contraction per 10-minute period, cervical dilatation of ≤2 cm as determined by pelvic examination, and intact membranes) by the University of Alberta Hospital Department of Laboratory Medicine and Pathology and from the National Disease Research Institute in Philadelphia. The reasons for preterm cesarean delivery included severe preeclampsia and pregnancy termination as a result of fetal anencephaly, severe oligohydramnios, or congenital malformations. Death at term was caused by meconium aspiration or congenital diaphragmatic hernia. At the time of autopsy the tissues were snap frozen in liquid nitrogen. These fetuses and neonates were stored at 4°C for no longer than 2 days before autopsy. Tests were performed to ensure that no significant deterioration of the mRNA had occurred during this period. Additionally, tissues from 3 deceased term neonates (between days 2 and 9 post partum) were supplied by the National Disease Research Institute. The causes of neonatal death were sudden infant death syndrome, shaken baby syndrome, and accident.
Samples were obtained between 57 and 90 days of gestation (first trimester, n = 6-9), between 91 and 180 days (second trimester, n = 5-8), from 181 days to term (third trimester, n = 3-5), or from neonates (postterm, n = 3). Gestational ages were calculated from the first day of the last menstrual period. We were not able to obtain samples of all tissues studied from each subject.
Women with clinical signs of inflammation or genital infection (fever, foul vaginal discharge) or bacterial vaginosis were excluded from the study. Additionally, patients were routinely tested for the presence of group B streptococci in the vaginal flora, and those with positive test results were not included in the study.
The relative abundance of PGHS-1 and PGHS-2 mRNA was determined in tissues by ribonuclease protection assays, which we have published. 8 Total RNA was extracted from tissues by using the acid guanidinium thiocyanatephenol-chloroform method. The RNA concentration of each sample was determined by absorbance at 260 nm. Human PGHS-1 and PGHS-2 complementary deoxyribonucleic acid was used for the development of complementary RNA probes for the ribonuclease protection assay. 9 Total tissue RNA (40 µg) was hybridized in solution with either the PGHS-1 or the PGHS-2 probe generated in transcription in vitro and digested with a mixture of ribonuclease A and ribonuclease T 1 , as previously described. 9 The protected RNA fragments were separated in 6% polyacrylamide denaturing gels and subjected to autoradiographic analysis.
For verification of the loading of RNA, the level of the constitutively expressed γ-actin was determined with ribonuclease protection assays. The human γ-actin probe was generated from a 270-nucleotide sequence of the C-terminal amino acid coding region. 10 The human cyclophilin probe was obtained by in vitro transcription of the pTRI-cyclophilin-human template from Ambion, Inc (Austin, Tex). Total RNA (40 µg) from the same samples used for PGHS-1 and PGHS-2 mRNA determinations was hybridized with the γ-actin probe under conditions identical to those described. In each assay, probes were hybridized to yeast transfer RNA to monitor nonspecific background hybridization. No probe protection was seen in these samples. Undigested probe was also subjected to electrophoresis in each assay for further verification of specific protection.
In each set of hybridization reactions a pooled tissue RNA preparation was included as PGHS-1, PGHS-2, and γ-actin standards. The standards were assigned a densitometric value of 1 on the autoradiographs, and PGHS-1, PGHS-2, and γ-actin densitometric intensities were normalized to that value. The PGHS densitometric values were expressed as a percentage of the γ-actin measured in the same RNA preparations. This normalization corrects for variations between individual ribonuclease protection assays and RNA sample quality. For all densitometric analyses, γ-actin was used as the loading control.
We were concerned about the possible degradation of RNA during the time between fetal or newborn death (stored at 4°C) and snap freezing of samples in liquid nitrogen. We therefore performed a test using human fetal amnion tissue in which tissues were either snap frozen at -80°C immediately on collection or stored for varying periods up to 2 days before freezing. This protocol mimicked the situation with the patient samples. Ribonucle-ase protection assays for PGHS-1 and PGHS-2 mRNA were then performed. No difference in mRNA abundance was observed for any period of storage at 4°C compared with fresh-frozen samples. A second check on RNA integrity was performed with each ribonuclease protection assay for the presence and uniformity of ribosomal RNA bands after agarose gel electrophoresis. Finally, all PGHS-1 and PGHS-2 mRNA abundance values were normalized (as described) to a loading control mRNA from the same samples.
Densitometric data were analyzed by 1-way analysis of variance. When a significant F value was obtained, variation was assessed by the Tukey test, and the level of significance was established at α = .05.
Results
Representative ribonuclease protection assay blots of PGHS-1, PGHS-2, and cyclophilin mRNA from human fetal lung, kidney, and intestine are shown in Fig 1. PGHS-1 mRNA levels. The fetal lung was the only organ in which PGHS-1 mRNA levels differed across trimesters (F 3, 16 = 5.5; P = .012), and this was a significant decrease (Fig 2, A) . The levels in the neonatal period were statistically lower than in the first trimester (P < .05). There was no change in the levels of PGHS-1 mRNA throughout gestation and into the newborn period in human fetal kidney or intestine (P > .2) (Fig 3, A,  and Fig 4, A) .
PGHS-2 mRNA levels.
Results indicate that the relative abundance of PGHS-2 mRNA increases with either gestational age or fetal development, or both, in the fetal lung (Fig 2, B) , kidney (Fig 3, B) , and intestine (Fig 4, B) . For example, in the fetal lung (Fig 2, B) there is an increase in PGHS-2 mRNA expression across trimesters and into the postnatal period (F 3, 15 = 27.6; P < .001). Examination by post hoc analysis revealed that fetal lung PGHS-2 mRNA levels were significantly elevated by the third trimester (P < .05) and that values tripled in the postnatal period (P < .05).
A similar trimester-dependent pattern of increasing PGHS-2 mRNA levels was evident in the fetal kidney (Fig  3, B) (F 3, 18 = 25.0; P < .001). Again, by the third trimester, PGHS-2 mRNA levels in the fetal kidney were significantly elevated over those levels indicative of the first trimester (P < .05), and the PGHS-2 mRNA continued to increase further during postnatal development (P < .05).
The profile of fetal intestine PGHS-2 mRNA levels (Fig  4, B) across trimesters was largely similar to the patterns measured from the fetal lung and the fetal kidney. There was a main effect of trimester on PGHS-2 mRNA levels (F 3, 23 = 9.48; P < .001), and by the third trimester the PGHS-2 mRNA levels had doubled from the levels of the second trimester and were significantly greater than the levels from first-trimester fetuses (P < .05). There was no further increase in the relative mRNA abundance in intestine after term birth, although levels remained elevated. We also examined other human fetal organs (heart, brain [cerebrum], and stomach) for PGHS-1 and PGHS-2 mRNA (data not shown). Each organ contained mRNA from both isoforms of enzyme in each trimester of pregnancy, but we did not obtain enough samples to make any judgments about relative abundance levels during pregnancy.
Comment
The clear conclusion from this study is that a significant and many-fold increase in PGHS-2 mRNA occurs throughout pregnancy in several human fetal tissues. This is unique for PGHS-2 mRNA, because PGHS-1 mRNA levels either stay constant throughout pregnancy or decrease, as in the lung. In the lung and kidney this increase in PGHS-2 mRNA expression continues through birth into the neonatal period. Although we did not plot the data on individual subjects at specific times in gestation because of the limited number of subjects and tissues available, examination of the individual data suggests a late-gestation increase in PGHS-2 mRNA expression. We recently published data demonstrating a strikingly similar pattern of a large increase in PGHS-2 mRNA expression in the human fetal membranes, amnion and chorion, beginning in late gestation, at approximately week 35. 8, 11 This is in contrast to PGHS-1 mRNA expression in human fetal membranes, which is fairly constant throughout pregnancy, increasing slightly, about 4-fold, at term. It is 
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also in contrast to the maternal decidua, which demonstrates no changes in either PGHS-1 or PGHS-2 mRNA expression throughout gestation. 8 These data were recently confirmed in the baboon decidua, which also does not demonstrate an increase in either PGHS-1 or PGHS-2 mRNA during pregnancy. 12 Furthermore, there is no increase in PGHS-1 or PGHS-2 mRNA expression in the lower segment of human myometrium in late gestation or with the onset of labor, 13 although a more recent article 14 presents conflicting data on human myometrium, suggesting that PGHS-2 mRNA levels do increase before the onset of labor. Nevertheless, there is a uniform pattern of expression in the fetus suggesting either that many human fetal tissues, nearly simultaneously and independently, increase their expression of PGHS-2 mRNA in late gestation or that a common control stimulus (eg, hormonal) coordinates the increased expression. There is precedent for a central mechanism.
Hypophysectomy in fetal lambs diminishes the late-gestation increase in placental PGHS activity and in maternal prostaglandin E 2 concentrations. 15 These authors suggested that luteinizing hormone may be the factor that stimulates prostaglandin synthesis. In other studies both cortisol and dexamethasone stimulated an increase in cultured amnion cell PGHS activity and in prostaglandin E 2 output. 16, 17 Alternatively, ligation of the bladder in adult mice stimulates an increase in PGHS-2 expression, suggesting the possibility of stretch as a stimulus. 18 Every effort was made in this study to exclude factors not associated with normal fetal development that may have influenced fetal PGHS mRNA expression; hence we excluded all samples associated with inflammation or preterm birth.
It is not known which of the enzyme isoforms is necessary to produce the prostaglandins for normal fetal development and physiologic characteristics, but evidence exists to suggest that PGHS-2 is vital for certain aspects of fetal organ development and physiologic features. Knockout mice homozygous for recessive PGHS-2 19, 20 are anephric, display cardiomyopathies, and generally die shortly after birth or do not survive to reproduc-tive age.
An important aspect of this knowledge of PGHS expression and activity in the developing human fetus has to do with tocolytic therapy to delay threatened or actual preterm labor and to prolong pregnancy in women. As evidence mounts to suggest that PGHS-2 mRNA, protein, and specific activity increase at term and before term in the fetal membranes and placental tissues of the human and other species, 8, 21, 22 efforts to study the effects of specific inhibitors of PGHS-2 enzymatic activity on altering the timing of human and animal preterm labor have been made. Sawdy et al 23 reported that the administration of nimesulide, a preferential PGHS-2 inhibitor, to a woman to prevent recurrent second-trimester loss was associated with an increase in amniotic fluid volume and preterm birth on withdrawal of treatment. In pregnant mice NS-398 (N-[2-(cyclohexgloxy)-4-nitro-phenyl]methane sulfonamide), another PGHS-2-selective inhibitor, prolonged normal gestation and blocked lipopolysaccharide-induced preterm labor. 24 Similarly, NS-398 blocked preterm labor induced by adrenocorticotropic hormone in sheep, 22 and meloxicam, a third PGHS-2 inhibitor, prolonged gestation in ewes administered the progesterone receptor blocker, mifepristone (RU 486), which normally shortens gestational length. 25 The mice were born healthy, and the lambs were apparently unaffected by the inhibitors, although detailed examination of newborn organ function and prostaglandin synthesis was not carried out in any study. 
It is important in studies such as these to determine the effects of specific PGHS-2 inhibitors on fetal and neonatal organ development and function. As cited earlier, it is clear that nonspecific prostaglandin synthesis inhibitors, such as aspirin and indomethacin, have deleterious effects on human renal development and function and on ductus arteriosus function. Further, their use during pregnancy is associated with a greater risk of intracranial hemorrhage and necrotizing enterocolitis. Whether PGHS-2 mRNA increases in fetal tissues before term, at the time of preterm birth, is not known; further, its relative importance in fetal development during the second and early third trimesters is also unknown. It is probable, however, that specific inhibitors of PGHS-2, although effective in delaying preterm labor, may not be safe for the fetus. Careful examination of this aspect of tocolytic therapy is warranted.
In summary, our results demonstrate that PGHS-2 mRNA increases in human fetal kidney, lung, and intestine in the third trimester and into the newborn period in some cases. The expression of PGHS-1 mRNA, on the other hand, remains constant or may decline in these tissues during gestation. The roles of prostaglandins from each of these enzyme isoforms in fetal development and physiologic features remain to be determined, as does the coordinated regulation of these increases in PGHS-2 expression.
